U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 311 - 320 of 1728 results

Status:
Investigational
Source:
NCT04502225: Not Applicable Interventional Recruiting Supine Hypertension
(2020)
Source URL:

Class (Stereo):
CHEMICAL (MIXED)

Status:
Investigational
Source:
INN:suncillin
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Suncillin is an antibacteria and antifungal agent produced in Phytera's laboratory from a cell culture of a plant. Suncillin was patented by Bristol-Myers Co. In 1968 for the Pseudomonas bacteria treatment but was never marketed.
Status:
Investigational
Source:
INN:sulfatroxazole
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)


Sulfatroxazole is a sulfamide derivative patented by Swiss multinational healthcare company F. Hoffmann-La Roche & Co., A.-G. as an antibacterial agent and bacteriostatic antibiotic. Sulfatroxazole competitively inhibits dihydropteroate synthase preventing the formation of dihydropteroic acid, a precursor of folic acid which is required for bacterial growth. Sulfatroxazole is a component present in various veterinary drugs.
Status:
Investigational
Source:
INN:sancycline
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

There is a little information around sancycline. It is known, that it was synthesized by Conover and co-workers in 1962 and it was antibacterial compound. It was proposed that sancycline binds to the 30S of bacterial ribosomal subunit and inhibiting protein translation by blocking entry of aminoacyl-tRNA into the ribosome A site.
Status:
Investigational
Source:
INN:stibosamine [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Stibosamine is a Salts of p-aminophenylstibinic acid and N-ethylethanamine patented by Hynson, Westcott & Dunning for the treatment kala-azar infection.
Status:
Investigational
Source:
INN:nibroxane
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Nibroxane, 5-bromo-2-methyl-5-nitro-m-dioxane, is a topically effective antimicrobial agent with a broad spectrum of activity. Nibroxane is unusual in that it not only possesses high microbiocidal activity against Gram positive (Staphylococcus uureus) and Gram negative (Pseudomonas aeruginosa) bacteria but also against yeasts (Candida albicans) and moulds (Aspergillus niger). In addition, the 5-bromo-5-nitro-m-dioxanes have, as a class of compounds, the distinct advantage of being chemically stable over a wide pH range. This inherent stability, coupled with its broad spectrum of microbiocidal activity, makes nibroxane an excellent candidate as a preservative for cosmetic and pharmaceutical formulations.
Status:
Investigational
Source:
INN:meglucycline
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Meglucycline is an antibiotic.
Status:
Investigational
Source:
INN:tigemonam
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Tigemonam is a dialkylazetidinone derivative patented by E. R. Squibb and Sons, Inc. as a beta-lactam agent useful for the treatment of bacterial infections. Of the orally active beta-lactams, tigemonam is one of the most potent, with a spectrum of activity similar to that of aztreonam and highly resistant to hydrolysis by the beta-lactamase enzymes. Tigemonam inhibits 90% of Escherichia coli, Klebsiella spp., Proteus spp., Salmonella spp., Haemophilus influenzae and Branhamella catarrhalis tested. In localized infections, tigemonam also demonstrated excellent in vivo activity. In acute pyelonephritis in mice caused by Escherichia coli or Proteus sp., tigemonam was very effective. In a rat lung model with Klebsiella pneumoniae, tigemonam was active with a median effective dose of 46 mg/kg compared with 160 mg/kg for cefaclor and over 200 mg/kg for amoxicillin.
Status:
Investigational
Source:
INN:quindecamine
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Quindecamine (also known as UCL-1407) is quinaldine derivative with antibiotic and fungicidal activity. Treatment of rats and mice with Quindecamine (250 mg/kg/ day) each day for 4 weeks followed by 500 mg/kg/day for 2 more weeks reduced spontaneous motility and body weight but produced no pathological abnormalities of the various organs studied. In vitro, the drug showed very good activity against Staphylococcus aureus, Streptococcus hemolyticus, Candida albicans, Trichophyton mentagrophytes, and T. vaginalis. The drug had very good activity in 180 human subjects with various bacterial and mycotic diseases of the skin and mucosa when applied as a 1% salve.
Status:
Investigational
Source:
INN:nitrodan
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Nitrodan is an anthelmintic drug. Nitrodan was effective when administered in feed against Hymenolepis nana and Syphacia obvelata infections in mice, Ascaridia galli infections in chickens, and Toxocara canis, Ancylostoma caninum, and Uncinaria stenocephala infections in dogs. This drug was not effective against Aspiculuris tetraptera, Nematospiroides dubius, and Nippostrongylus muris in mice or Toxascaris leonina in dogs. Long-term continuous feeding of 230 ppm nitrodan should provide an easy and efficient means of reducing infections of A. galli in chickens, and T. canis, A. caninum, and U. stenocephala in dogs, while minimizing opportunities for reexposure.